Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03633578
Other study ID # LOCAL/2017/AH-01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2018
Est. completion date May 17, 2018

Study information

Verified date December 2020
Source Centre Hospitalier Universitaire de Nimes
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Motor control, notably expressed through the complexity of the variability of the locomotor pattern, is disturbed at the central level by an apprehension of pain and movement, more than pain itself (or by biomechanical / structural damage of the spine) in chronic low back pain (cLBP) patients. The aim of this study is to control that variability is reduced during gait at comfortable level and to test that distraction can reduce pain avoidance and therefore increase variability in cLBP patients.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date May 17, 2018
Est. primary completion date May 17, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - The patient must have his informed consent and signed the consent form. - The patient must be affiliated or beneficiary of a health insurance plan - The patient is at least 18 years old and under 75 years old - Patients with common chronic low back pain for more than 6 months Exclusion Criteria: - The subject participates in another interventional study - The subject is in an exclusion period determined by a previous study - The subject is under the protection of justice, guardianship or curatorship - The subject refuses to sign the consent - It is impossible to inform the subject - Chronic symptomatic low back pain (tumoral pathology, infectious, or progressive inflammatory) - Unable to walk for more than 10 minutes (during interrogation) - Lower limb pain (EVA lower limb (s) = Lumbar EVA)

Study Design


Intervention

Behavioral:
walk test
The patient will have to walk on a treadmill in four different conditions: without distraction at preferential speed with distraction at preferential speed without distraction at the speed of 130% of the preferential speed with distraction at the speed of 130% of the preferential speed

Locations

Country Name City State
France Nimes University Hospital Nîmes

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Estimation of the fractal exponent when walking without distraction at preferential speed [0,5; 1,5] Day 0
Primary Estimation of the fractal exponent when walking with distraction at preferential speed [0,5; 1,5] Day 0
Primary Estimation of the fractal exponent when walking without distraction at the speed of 130% of the preferential speed [0,5; 1,5] Day 0
Primary Estimation of the fractal exponent when walking with distraction at the speed of 130% of the preferential speed [0,5; 1,5] Day 0
Secondary EVA after walking without distraction at preferential speed [0; 100] Day 0
Secondary EVA after walking with distraction at preferential speed [0; 100] Day 0
Secondary EVA after walking without distraction at the speed of 130% of the preferential speed [0; 100] Day 0
Secondary EVA after walking with distraction at the speed of 130% of the preferential speed [0; 100] Day 0
Secondary Reaction time to auditory stimuli without distraction at preferential speed second Day 0
Secondary Reaction time to auditory stimuli with distraction at preferential speed second Day 0
Secondary Reaction time to auditory stimuli without distraction at the speed of 130% of the preferential speed second Day 0
Secondary Reaction time to auditory stimuli with distraction at the speed of 130% of the preferential speed second Day 0
Secondary Tampa Scale for kinesophobia The total score ranges between 17 and 68. A high value on the Tampa Scale for the "Tampa Scale for kinesophobia" indicates a high degree of kinesiophobia Day 0
Secondary Dallas Pain Questionnaire for Back Pain This questionnaire has been designed to give health care provider information as to how pain affects daily activities. It assesses the impact of low back pain (LBP) on four components (daily activities, work and leisure activities, anxiety/depression, and social interest) (expressed as a value between 0 and 100) of daily life.The higher the score, the more the low back pain has an impact on the quality of life. Day 0
Secondary Quebec Back Pain Disability Index The item scores were summed for a total score between 0 and 100, with higher numbers representing greater levels of disability. Day 0
Secondary Fear Avoidance Belief Questionnaire (FABQ) The Fear Avoidance Belief Questionnaire is a two-part questionnaire assessing fear, avoidance, and beliefs about professional activity and physical activity.
The FABQ physical activity score of 14 responds better to a cognitive/behavioral approach and de-emphasize the traditional pain specific treatment goals. The "Fear Avoidance Belief Questionnaire" Work score that is >18 has a decrease likelihood of success from a joint manipulation/mobilization treatment approach. The "Fear Avoidance Belief Questionnaire" Work score of 34 or greater increases the risk for prolonged disability and will most likely require a multi-disciplinary approach to treatment.
Day 0
Secondary Hospital and Anxiety Depression Scale Score:
0-7 = Normal 8-10 = Borderline abnormal (borderline case) 11-21 = Abnormal (case)
Day 0
See also
  Status Clinical Trial Phase
Completed NCT03243084 - Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy N/A
Suspended NCT04735185 - Stem Cells vs. Steroids for Discogenic Back Pain N/A
Completed NCT03162952 - RAND Center of Excellence for the Study of Appropriateness of Care in CAM
Completed NCT03240146 - Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain N/A
Completed NCT05282589 - Lumbopelvic Manipulation Effects on Fatigue in Chronic Low Back Pain Patients N/A
Completed NCT03637998 - Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain N/A
Recruiting NCT02289170 - Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100) N/A
Active, not recruiting NCT01944163 - The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain N/A
Completed NCT02231554 - Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial N/A
Recruiting NCT02063503 - Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients N/A
Completed NCT01704677 - Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up N/A
Terminated NCT01620775 - MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain N/A
Completed NCT01177241 - Cytochrome P450 Pharmacokinetic DDIs Among Patients With Chronic Low Back Pain Taking Opioids N/A
Completed NCT01177280 - Prevalence of Potential Cytochrome P450 Pharmacokinetic Incident Drug-Drug Interactions Among Chronic Low Back Pain Patients Taking Opioid Analgesics and Associated Economic Outcomes N/A
Completed NCT01177254 - Exposure to Potential Cytochrome P450 Pharmacokinetic Drug-Drug Interactions Among Osteoarthritis Patients: Incremental Risk of Multiple Prescriptions N/A
Completed NCT01490905 - A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain Phase 4
Completed NCT00984815 - Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment Phase 3
Completed NCT00761150 - Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) Phase 3
Completed NCT00767806 - A Study for Patient With Chronic Low Back Pain Phase 3
Completed NCT00763321 - Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP) Phase 3